Evidence map›Paper›PMID 33912045›Full record

ArticleFrontiers in pharmacology2021

Health Impact and Cost-Effectiveness of Implementing Gender-Neutral Vaccination With the 9-Valent Human Papillomavirus Vaccine in Belgium.

Steven Simoens, Andre Bento-Abreu, Barbara Merckx, Sophie Joubert, Steve Vermeersch, Andrew Pavelyev, Stefan Varga, Edith Morais

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. The effects of human papillomavirus vaccination in Japan.Human vaccines & immunotherapeutics · 2025
    Article
  3. Article
  4. Framework for developing cost-effectiveness analysis threshold: the case of Egypt.The Journal of the Egyptian Public Health Association · 2024
    Article
  5. Economic Burden of Cervical Cancer in Bulgaria.International journal of environmental research and public health · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Steven SimoensKU Leuven Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium.
Andre Bento-AbreuMerck Sharp & Dohme, Brussels, Belgium.
Barbara MerckxMerck Sharp & Dohme, Brussels, Belgium.
Sophie JoubertMerck Sharp & Dohme, Brussels, Belgium.
Steve VermeerschMerck Sharp & Dohme, Brussels, Belgium.
Andrew PavelyevMerck & Co., Inc., Kenilworth, NJ, United States.
Stefan VargaMerck & Co., Inc., Kenilworth, NJ, United States.
Edith MoraisMerck Sharp & Dohme, Lyon, France.
MSD (Belgium) · BEMerck & Co., Inc., Rahway, NJ, USA (United States) · USKU Leuven · BEMSD (France) · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

9-valentBelgiumcervical cancercost-effectivenessgenital wartsHPVhuman papillomavirusvaccine

Identifiers

PMID33912045
PMCPMC8072375
OpenAlexW3155853644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.